10% decrease in Adderall prescription fills in US since fall 2022, due to shortage linked to increased diagnoses, DEA quotas, and opioid lawsuit impact.
A survey by Truveta reveals a 10% decrease in Adderall prescription fills per eligible population in the US since fall 2022. The shortage, first announced by the FDA, has led to an 11.4% lower prescription fill rate in the first five months of 2023 compared to 2022. The shortage is attributed to factors such as increased ADHD diagnoses, DEA production quotas, and drug manufacturers' reduced production due to the opioid lawsuit.
April 05, 2024
4 Articles